|By PR Newswire||
|March 20, 2014 08:15 AM EDT||
GUILDFORD, England, March 20, 2014 /PRNewswire/ --
- Discover how smart technologies can help people with diabetes better understand their insulin therapy and health improvements -
MyStarExtra®, a new generation blood glucose monitoring device developed by Sanofi, is now available in the United Kingdom. MyStar Extra® is the first self-monitoring device that provides estimates of the HbA1c value, a key indicator for long-term glucose control.[i],[ii] This unique blood glucose monitoring device may help people with diabetes better understand the meaning of their test results in the context of overall treatment goals. Several extra features of the device may help people with diabetes stay motivated and engaged in managing their insulin therapy.
"Living with Type 1 diabetes is hard work with no time off. It's a constant balancing act between ensuring I have the correct amounts of insulin to keep my blood glucose at safe levels. This takes motivation. For me to stay motivated in my diabetes management I need accurate and consistent data from my blood glucose device. Without this, I am unable to make the informed decisions that I need to manage my diabetes the way that I want to. Next to insulin, reliable data from my blood glucose device is the most important tool that I have to manage my diabetes. I welcome any new technologies that may support me stay motivated and engaged" said Chris Aldred, @grumpy_pumper, http://www.the-grumpy-pumper.com/
MyStar Extra® provides key benefits to support patients manage their insulin therapy
The new MyStar Extra® blood glucose device from Sanofi provides relevant blood glucose information and comes with new features. It can help keep patients motivated to take an active role in managing their insulin therapy.[iii] One of the parameters used to assess the level of glycaemic control in people with diabetes is the HbA1c (haemoglobin A1c) value. The HbA1c value reflects average glucose levels over the previous three months and is therefore regarded as an indicator for long term glucose control.[v],[vi] Until now, HbA1c levels were obtained through a laboratory test which patients receive on average once or twice a year, but now MyStar Extra® can provide an HbA1c estimate. The device uses unique algorithms to provide estimates of HbA1c. While this does not replace the laboratory test, it provides more immediate feedback on therapy progress.[iv],[vii]
In addition to the HbA1c estimate, MyStar Extra® calculates a three-day fasting plasma glucose average (FPG) and FPG trends. For people with diabetes who find it challenging to follow treatment regimes, three-day fasting averages simplify access to practical glucose information. FPG values measure the blood glucose concentration in a blood sample after an overnight fast. Three-day FPG averages are commonly used to titrate basal insulin, one of the most used treatment approaches in type 2 diabetes.[viii] The innovative technology of MyStar Extra®, simplifies diabetes management through using smart technology to produce immediate feedback.
"We are delighted that MyStar Extra® will now be available for people with diabetes in the United Kingdom. Sanofi has developed MyStar Extra® with the needs of people using or starting on insulin in mind. The device provides the personal glucose information people with diabetes need in a simple form, enabling them to manage their diabetes and track their long-term therapy success. This is what smart technology is all about: MyStar Extra® helps patients understand control of their diabetes better, and helps to motivate them to stick to their recommended therapy", said Becky Reeve, Head of Professional Relations, Sanofi UK.
MyStar Extra® and the new lancing device MyStar SylkFeel® will be available in the United Kingdom from March 2014. They will complement the MyStar® portfolio of Sanofi, combining devices, services and guidance for simple and effective diabetes management.
Diabetes is a chronic disease that occurs as type 1 diabetes, which is an autoimmune disease characterized by the lack of insulin (the hormone that regulates blood glucose concentrations) production by the pancreas, and type 2, a metabolic disorder in which there are two main biological defects: a deficient production of insulin and reduced ability of the body to respond to the insulin being produced. Type 1 and type 2 diabetes are characterized by an increase in blood glucose concentrations (hyperglycaemia). Over time, uncontrolled hyperglycaemia leads to macro vascular and micro vascular complications of diabetes. Macro vascular complications, which affect the large blood vessels, include heart attack, stroke and peripheral vascular disease. Micro vascular complications affect the small blood vessels of the eyes (retinopathy), kidney (nephropathy) and nerves (neuropathy). The global incidence of diabetes is growing at an alarming rate.
A blood glucose monitoring device reads the amount of sugar released in the blood, which has previously been absorbed from food or built up by the body. The glucose value is measured with a small sample of blood, usually taken from a finger and then applied to a disposable test strip. Based on blood glucose readings, many people with diabetes have to adjust their medication or insulin doses to keep the amount of glucose in the blood to target levels.
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services and devices, including blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
i. Fisher WA et al. What Primary Care Providers Can Do to Address Barriers to Self-Monitoring of Blood Glucose. Clinical Diabetes 2013;31(1):34-42.
ii. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998; 352: 837-53.
iii Delamater A, et al. Improving patient adherence. Clinical Diabetes April 2006;24 (2): 71-77.
iv MyStar Extra™ Blood Glucose Monitoring System Owner's Guide.
v Clinical Guideline Task Force, Global Guidelines for Type 2 diabetes, International Diabetes Federation, 2005. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed July 2013.
vi World Health Organization, Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus, 2011. Available at: http://www.who.int/diabetes/publications/report-hba1c_2011.pdf. Accessed July 2013.
vii Cagliero E, et al. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care 1999;22:1785-1789.
viii Strange et al. J Diabetes Sci Technol 2007;1(4):540-548.
ix Kovatchev BP, et al. Effect of automated bio-behavioral feedback on the control of type 1 diabetes. Diabetes Care. 2011 Feb; 34 (2):302-7. Epub 2011 Jan 7.
x Breton M. Robustness of dynamical real-time estimation of A1C using routine self-monitoring of blood glucose (SMBG) data Abstr 1079 EASD 2013
The Internet of Things is in the early stages of mainstream deployment but it promises to unlock value and rapidly transform how organizations manage, operationalize, and monetize their assets. IoT is a complex structure of hardware, sensors, applications, analytics and devices that need to be able to communicate geographically and across all functions. Once the data is collected from numerous endpoints, the challenge then becomes converting it into actionable insight.
Sep. 4, 2015 12:30 PM EDT Reads: 113
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
Sep. 4, 2015 12:00 PM EDT Reads: 496
SYS-CON Events announced today that Micron Technology, Inc., a global leader in advanced semiconductor systems, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Micron’s broad portfolio of high-performance memory technologies – including DRAM, NAND and NOR Flash – is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of tech...
Sep. 4, 2015 12:00 PM EDT Reads: 292
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, FinancialForce.com was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts...
Sep. 4, 2015 12:00 PM EDT Reads: 103
U.S. companies are desperately trying to recruit and hire skilled software engineers and developers, but there is simply not enough quality talent to go around. Tiempo Development is a nearshore software development company. Our headquarters are in AZ, but we are a pioneer and leader in outsourcing to Mexico, based on our three software development centers there. We have a proven process and we are experts at providing our customers with powerful solutions. We transform ideas into reality.
Sep. 4, 2015 11:45 AM EDT Reads: 584
As more and more data is generated from a variety of connected devices, the need to get insights from this data and predict future behavior and trends is increasingly essential for businesses. Real-time stream processing is needed in a variety of different industries such as Manufacturing, Oil and Gas, Automobile, Finance, Online Retail, Smart Grids, and Healthcare. Azure Stream Analytics is a fully managed distributed stream computation service that provides low latency, scalable processing of ...
Sep. 4, 2015 11:45 AM EDT Reads: 398
In 2014, the market witnessed a massive migration to the cloud as enterprises finally overcame their fears of the cloud’s viability, security, etc. Over the past 18 months, AWS, Google and Microsoft have waged an ongoing battle through a wave of price cuts and new features. For IT executives, sorting through all the noise to make the best cloud investment decisions has become daunting. Enterprises can and are moving away from a "one size fits all" cloud approach. The new competitive field has ...
Sep. 4, 2015 11:00 AM EDT Reads: 191
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
Sep. 4, 2015 11:00 AM EDT Reads: 427
Everyone talks about continuous integration and continuous delivery but those are just two ends of the pipeline. In the middle of DevOps is continuous testing (CT), and many organizations are struggling to implement continuous testing effectively. After all, without continuous testing there is no delivery. And Lab-As-A-Service (LaaS) enhances the CT with dynamic on-demand self-serve test topologies. CT together with LAAS make a powerful combination that perfectly serves complex software developm...
Sep. 4, 2015 11:00 AM EDT Reads: 249
17th Cloud Expo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises ar...
Sep. 4, 2015 11:00 AM EDT Reads: 1,615
SYS-CON Events announced today that the "Second Containers & Microservices Expo" will take place November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities.
Sep. 4, 2015 10:45 AM EDT Reads: 662
Moving an existing on-premise infrastructure into the cloud can be a complex and daunting proposition. It is critical to understand the benefits as well as the challenges associated with either a full or hybrid approach. In his session at 17th Cloud Expo, Richard Weiss, Principal Consultant at Pythian, will present a roadmap that can be leveraged by any organization to plan, analyze, evaluate and execute on a cloud migration solution. He will review the five major cloud transformation phases a...
Sep. 4, 2015 10:15 AM EDT Reads: 128
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Sep. 4, 2015 10:00 AM EDT Reads: 870
WebRTC services have already permeated corporate communications in the form of videoconferencing solutions. However, WebRTC has the potential of going beyond and catalyzing a new class of services providing more than calls with capabilities such as mass-scale real-time media broadcasting, enriched and augmented video, person-to-machine and machine-to-machine communications. In his session at @ThingsExpo, Luis Lopez, CEO of Kurento, will introduce the technologies required for implementing thes...
Sep. 4, 2015 10:00 AM EDT Reads: 135
eCube Systems has released NXTmonitor, a full featured application orchestration solution. NXTmonitor, which inherited the code base of NXTminder, has been extended to support multi-discipline processes and will act as a DevOps utility in a heterogeneous enterprise environment. Previously, NXTminder was packaged with NXTera middleware to configure and manage Entera and NXTera RPC servers. “Since we are widening the focus of this solution to DevOps, we felt the need to change the name to NXTmon...
Sep. 4, 2015 10:00 AM EDT Reads: 146